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Highligts 19 
 20 
 Six sheep were administered 4 and 6 mg/kg tramadol and saline intravenously. 21 
 Pharmacokinetics analysis and mechanical nociceptive threshold test were performed. 22 
 Pharmacokinetics parameters of tramadol were similar after the two doses. 23 
 No mechanical antinociceptive effects of tramadol were reported. 24 
 Further studies are warranted to assess the efficacy of tramadol in sheep. 25 
 26 
.  27 
   28 
 29 
 30 
Abstract 31 
 Although sheep are widely used as an experimental model for various surgical procedures 32 
there is a paucity of data on the pharmacokinetics and efficacy of analgesic drugs in this species. 33 
The aim of this study was to investigate the pharmacokinetics of intravenously (IV) administered 34 
tramadol and its active metabolite O-desmethyltramadol (M1) and to assess the mechanical 35 
antinociceptive effects in sheep.  36 
 37 
 In a prospective, randomized, blinded study, six healthy adult sheep were given 4 and 6 mg/kg 38 
tramadol and saline IV in a cross-over design with a 2-week wash-out period. At predetermined 39 
time points blood samples were collected and physiological parameters and mechanical nociceptive 40 
threshold (MNT) values recorded. The analytical determination of tramadol and M1 was performed 41 
using high performance liquid chromatography. Pharmacokinetic parameters fitted a two- and a 42 
non-compartmental model for tramadol and M1, respectively. Normally distributed data were 43 
analysed by a repeated mixed linear model. 44 
 45 
 Plasma concentration vs. time profiles of tramadol and M1 were similar after the two doses. 46 
Tramadol and M1 plasma levels decreased rapidly in the systemic circulation, with both 47 
undetectable after 6 h following drug administration. Physiological parameters did not differ 48 
Page 2 of 22
3 
 
between groups; MNT values were not statistically significant between groups at any time point. It 49 
was concluded that although tramadol and M1 concentrations in plasma were above the human 50 
minimum analgesic concentration after both treatments, no mechanical antinociceptive effects of 51 
tramadol were reported. Further studies are warranted to assess the analgesic efficacy of tramadol in 52 
sheep. 53 
 54 
Keywords: Tramadol; Sheep; Pharmacokinetics; Analgesia; Mechanical Nociceptive Threshold 55 
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Introduction 57 
 Sheep are widely used as an experimental model for various surgical procedures (Coulter et 58 
al., 2009). In spite of this, there is a paucity of data regarding the pharmacokinetics and efficacy of 59 
analgesic drugs in this species. There is a clear need to identify analgesic drugs, dose and dose 60 
interval for use in sheep during invasive experimental procedures. 61 
 62 
 Tramadol is an analgesic drug widely used in people and in small animals; it possesses a weak 63 
agonist action against the mu (µ) opioid receptor and inhibits the reuptake of norepinephrine and 64 
serotonin (Raffa et al., 1992). The active metabolite, O-desmethyltramadol (M1) has an affinity for 65 
the μ opioid receptor that is 300× greater than that of tramadol (Grond and Sablotzky, 2004). No 66 
studies investigating the analgesic efficacy of tramadol in sheep have been performed so far. 67 
However, the pharmacokinetics and biotransformation of tramadol have been studied in several 68 
animal species including the dog, cat, goat, llama, alpaca, horse and donkey (KuKanich and Papich, 69 
2004; Giorgi et al., 2007, 2009a; de Sousa et al., 2008; Pypendop and Ilkiw, 2008; Cox et al., 2011; 70 
Stewart et al., 2011; Edmondson et al., 2012), highlighting species-specific differences in the kinetic 71 
profiles of both the parent drug and its metabolites. 72 
 73 
 Although the effectiveness of tramadol is still unclear in veterinary medicine (Giorgi, 2012), 74 
there are reports confirming the analgesic efficacy of tramadol for the management of peri-operative 75 
pain in other ruminants (Bigham et al., 2010; Habibian et al., 2011; Dehkordi et al., 2012). 76 
 77 
 To evaluate the analgesic or antihyperalgesic efficacy of opioid drugs, nociceptive threshold 78 
testing, or analgesiometry, can be used. This consists of the application of a measurable stimulus, 79 
usually mechanical, thermal or electrical, in order to obtain a clear behavioural response and record 80 
the threshold at which the animal responded. If the tested drug exerts analgesic or antihyperalgesic 81 
effect, the threshold will either increase or remain unchanged (for example, when thresholds are 82 
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measured following induction of inflammation). Mechanical nociceptive threshold (MNT) testing 83 
devices have already been tested and validated in sheep (Nolan et al., 1987a; Musk et al., 2014).  84 
 85 
 The aim of the present study was to investigate the pharmacokinetic profile and 86 
antinociceptive efficacy of two different doses of tramadol administered intravenously (IV) to 87 
sheep. 88 
 89 
Materials and methods 90 
Animals and treatments 91 
 Six female adult Brogna sheep, body mass between 38 and 55 kg, were enrolled in the study, 92 
which was performed with approval from the Ethical Committee for Animal Experimentation of the 93 
University of Padua (CEASA 80/2012, 30 April 2013) and according to EC Council Directive 94 
86/609EEC (Council of the European Communities, 1986).  95 
 96 
 All animals were considered healthy based on clinical examination and haematological 97 
analyses. Sheep were kept indoors in a group pen (400 × 400 cm) in the Large Animal Facility at 98 
the University of Padua and fed a commercial pellet and hay diet. On the day of the experiment, 99 
three sheep were moved into individual stalls where the animals remained in visual contact with 100 
each other. The dimensions of each pen were: length 160 cm, width 66 cm and height 110 cm. Pens 101 
were bedded with straw. Sheep were acclimatized to the stalls, handlers, the MNT probe and testing 102 
procedure prior to commencing the study. Sheep were deprived of food for 8 h prior to the start of 103 
the experiment while water was available ad libitum. Hay and water were available ad libitum 2 h 104 
after treatment administration.  105 
 106 
 Two 14G catheters (Delta Ven, DeltaMed) were placed in the right and left jugular veins, to 107 
allow both treatment administration and collection of blood for the pharmacokinetic analysis. All 108 
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six sheep received the following three treatments IV over 2 min via the left jugular catheter: (1) 109 
tramadol 4 mg/kg (Group T4) (Tramadolo Hexal Ag), (2) tramadol 6 mg/kg (Group T6), and (3) 5 110 
mL of sodium chloride 0.9% solution (Group SAL). Drugs were administered in a randomly 111 
allocated, crossover design with a 2-week wash out period between treatments. Investigators were 112 
blinded to treatment allocation. 113 
 114 
Blood sampling and clinical evaluation 115 
 Five millilitres of blood were collected from the right jugular vein before drug (or saline) 116 
administration, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 12 and 24 h after administration. Whole 117 
blood was placed in lithium-heparinized tubes and centrifuged at 2000 g for 5 min. The harvested 118 
plasma was frozen at -80 °C until pharmacokinetic analysis was performed. 119 
 120 
 Immediately before and 15, 30 min and 1, 1.5, 2, 4, 6, 8, 10 and 12 h after drug 121 
administration, heart and respiratory rates were determined by thoracic auscultation and observation 122 
of thoracic excursions respectively. Rectal temperature and reticulo-ruminal motility, assessed by 123 
auscultation of the rumen (number of cycles in 5 min), were monitored starting from 30 min after 124 
drug administration. Sedation was quantified using a 0-100 mm visual analogue scale (VAS) scale 125 
where 0 mm was considered no sedation and 100 was considered very deep 126 
sedation/unconsciousness. Any adverse events attributed to the drug treatment were noted 127 
throughout the course of the study. 128 
 129 
MNT Testing  130 
 MNT was measured by a single investigator using the ProdPro (Topcat Metrology), as 131 
described elsewhere (Dixon et al., 2010). Briefly, this mechanical testing device comprises a cuff 132 
with a 2 mm hemispheric blunt pin fixed on a rolling diaphragm actuator and is applied 133 
perpendicular to the skin of the test area, in this case the dorsal aspect of the right metacarpus 134 
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approximately 4 cm below the carpus. The pin was pushed against the skin with a force which was 135 
applied manually by a syringe, connected to non-distensible tubing via a digital meter which 136 
displayed the force exerted, until a clear withdrawal response (leg lift, head turn, weight bearing on 137 
the contra-lateral limb) was evoked. The force at which the sheep responded with a clear 138 
withdrawal response was recorded as the MNT. A dummy actuator, identical to the test actuator 139 
apart from the fact that it did not contain the pin was secured to the contra-lateral limb. A cut off 140 
point was set at 25 N in order to prevent tissue trauma should a clear withdrawal response not be 141 
elicited.  142 
 143 
 The MNT was measured prior to blood collection at time point 0, immediately before drug 144 
administration (baseline), 15, 30, 45 min and 1, 1.5, 2, 4, 6, 8, 10 and 12 h after drug administration. 145 
In order to calculate the MNT, three measurements were performed at each time point with an 146 
interval of at least 2 min between each measurement and the mean was used for statistical analysis; 147 
five tests were performed and averaged to obtain the baseline MNT. 148 
 149 
Tramadol and M1 determination in blood  150 
 Based on a previously published high performance liquid chromatography (HPLC) technique 151 
(Giorgi et al., 2009b), the analytical method was briefly re-validated in sheep plasma. The HPLC 152 
was a liquid chromatographic system (Jasco) consisting of high-pressure mixer pump (model PU 153 
980 Plus), spectrofluorometric detector (model 2020 Plus) and a 20 μL loop. Data were processed 154 
by Borwin software (Jasco). Chromatographic separation assay was performed by a Luna C18 155 
ODS2 analytical column (150 × 4.6 mm inner diameter, 3 μm particle size, Phenomenex) 156 
maintained at 25 °C. The mobile phase consisted of acetonitrile:buffer (20 mM sodium dihydrogen 157 
phosphate, 30 mM sodium dodecyl sulfate, and 15 mM triethylamine, adjusted to pH 3.9 with 158 
phosphoric acid) (40:60 V/V) at a flow rate of 0.8 mL/min. Excitation and emission wavelengths 159 
were 275 and 300 nm, respectively. The analytical method used in this study was able to 160 
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differentiate the three main metabolites (M1, M2 and M5). However, the M2 and M5 plasma 161 
concentrations are not presented here as they are inactive metabolites and hence of negligible 162 
importance for the study. 163 
 164 
Pharmacokinetic analysis 165 
 The pharmacokinetic parameters were calculated for each subject from tramadol and M1 166 
plasma concentrations vs. time curves using WinNonLin v 5.3 (Pharsight Corp). The comparison 167 
between competing models (one- vs. two-compartment) was made using the Akaike test. The best 168 
fit was described by a two-compartment open and a non-compartmental model, for tramadol and 169 
M1, respectively. The area under the concentration vs. time curve (AUC0-) was calculated using 170 
the linear trapezoidal rule (Gibaldi and Perrier, 1982). 171 
 172 
Statistical analysis 173 
 Sample size calculations were performed before commencing the study. For a two way 174 
repeated measures ANOVA with a difference between ∆ MNT means (∆ MNT= MNT value at a 175 
specific time point minus baseline MNT value) of 3.5 N, standard deviation (SD) =2, β = 0.8 and α= 176 
0.05, a minimum of 6 animals per group were required. Residuals of repeated measures for ∆ MNT, 177 
heart rate, respiratory rate, body temperature were analysed for normality using the Shapiro-Wilk 178 
test.  179 
 180 
 Normally distributed data were analysed by a repeated mixed linear model with the fixed 181 
effects of treatment, time and their interaction and animal as a random effect (Littell et al., 1998). 182 
Reticulo-ruminal motility was analysed by a nonparametric approach (Kruskal-Wallis) to test the 183 
effect of treatment at the different time points. Data analyses were performed using SAS statistical 184 
software (version 9.3, SAS Institute). P values < 0.05 were deemed significant.  185 
 186 
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Results 187 
Pharmacokinetics 188 
 The tramadol and M1 concentrations vs. time after IV administration of 4 and 6 mg/kg of 189 
tramadol are shown in Fig. 1. The limits of detection (LOD) were 1 ng/mL and 3 ng/mL and the 190 
limits of quantification (LOQ) were 5 ng/mL and 10 ng/mL for T and M1, respectively. The values 191 
of precision for both analytes were always ≤ 9.8 (CV%), while accuracy was < 7.3%. 192 
 193 
 At the first time point (5 min) the plasma concentrations of tramadol were 1.29 ± 0.17 µg/mL 194 
and 1.56 ± 0.10 µg/mL following treatment with 4 mg/kg and 6 mg/kg tramadol, respectively. At 195 
the subsequent time points, tramadol plasma concentrations decreased rapidly for both treatments 196 
and were detectable in all animals only up to 4 h post-administration. At 6 h, tramadol was 197 
detectable in 5/6 sheep after treatment with 6 mg/kg and following administration of 4 mg/kg, was 198 
detectable at this time point in 4/6 animals. M1 was detectable in the plasma 5 min after tramadol 199 
administration, with a concentration equal to 0.13 ± 0.02 and 0.14 ± 0.03 µg/mL after 200 
administration of 4 and 6 mg/kg of tramadol, respectively. Similar plasma concentrations were 201 
maintained up to 45 min and then plasma concentrations decreased over the next 4 h. At time points 202 
later than 4 h, plasma concentrations of M1 were < LOQ. The most important pharmacokinetic 203 
parameters of tramadol and M1 are reported in Tables 1 and 2, respectively. 204 
 205 
Clinical evaluations 206 
 Mild self-limiting adverse events were noticed in all animals in Group T6 and in four animals 207 
in Group T4. These included tremors, muscle fasciculation, ataxia, agitation, urination and 208 
defecation that started 15-30 s after the beginning of drug administration and lasted for a maximum 209 
of 10 min. The severity of adverse events was greater in Group T6 but in all cases they 210 
spontaneously resolved. No adverse events were recorded in Group SAL. Heart rate, respiratory 211 
rate, temperature and reticulo-ruminal motility were not statistically different within each group 212 
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compared to baseline values or between groups at any time points (P > 0.05). No sedation was 213 
observed during the experiment in any group (VAS = 0 mm). 214 
 215 
MNT testing  216 
 Animals reacted to the MNT stimulation with a leg lift or head turn. The cut off value of 25 N 217 
was never reached during the study and no signs of tissue trauma or lameness were observed in 218 
sheep. There were no significant differences between groups in MNT baseline values; the overall 219 
baseline MNT was 8 ± 1.9 N. 220 
 221 
 There were no differences in ∆ MNT between groups at any time point (P > 0.05). 222 
Independently from treatment, at 15 and 30 min post-administration the ∆ MNT values were 223 
significantly higher than those observed from the 360 min time point onwards (P < 0.001). 224 
MNT values are shown in Fig. 2. Within-group comparisons showed that there were no 225 
statistically significant differences between the basal MNT and the MNT at any different time point 226 
(P > 0.05).  227 
 228 
Discussion 229 
 Sheep are widely used for invasive biomedical research but there are limited data on analgesic 230 
drug administration in this species. Few analgesic drugs have marketing authorisations for use in 231 
ruminants but those that are available include non-steroidal anti-inflammatory drugs (NSAIDs), α2-232 
agonists and local anaesthetic agents. In people, tramadol provides good analgesia with only mild 233 
effects on cardio-respiratory function and intestinal motility (Raffa et al., 1992) and is not currently 234 
subject to Controlled Drug legislation in Europe.  235 
 236 
 The tramadol doses chosen in the present study were extrapolated from previous studies in 237 
other ruminant species (de Sousa et al., 2008; Cox et al., 2011; Edmondson et al., 2012). A 238 
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pharmacokinetic study in goats evaluated 2 mg/kg tramadol (de Sousa et al., 2008) and the resulting 239 
data suggested that 4 mg/kg would be an appropriate dose to achieve plasma concentrations that 240 
might be consistent with analgesia, although antinociceptive/analgesic efficacy was not measured 241 
concurrently in that study. 242 
 243 
 The plasma concentration vs. time profiles (Fig. 1) of tramadol and M1 were similar after the 244 
two doses. Blood concentrations of tramadol in sheep declined quickly as evidenced by the very 245 
short half-life and high clearance value after administration of 4 and 6 mg/kg. The elimination half-246 
life values in this study were lower than those observed in other species such as goats (0.94 h) (de 247 
Sousa et al., 2008), alpacas (0.78-0.85 h) (Giorgi et al., 2010; Edmondson et al., 2012), and llamas 248 
(2.12 h) (Cox et al., 2011).  249 
 250 
 The formation of the active metabolite M1 was observed in all sheep. This is in agreement 251 
with an earlier study in goats (de Sousa et al., 2008), while in alpacas (Giorgi et al., 2010) M1 was 252 
detected in only 1/8 treated animals. In our study, the ratio of AUCs for M1/T was equal to 0.36 and 253 
0.43 after IV administration of 4 mg/kg and 6 mg/kg of tramadol, respectively. These similar values 254 
suggest that the metabolic system of the sheep was not saturated at doses up to 6 mg/kg. This ratio 255 
value is similar to that found in dogs (0.31) by KuKanich and Papich (2004), and in goats (0.28) by 256 
de Sousa et al. (2008), and lower than that observed in llamas (0.94) by Cox et al. (2011) and in cats 257 
(AUCs ratio M1/T >1) by Pypendop and Ilkiw (2008). These comparisons indicate that M1 has a 258 
more prominent role in the pharmacokinetics of tramadol in cats and llamas compared to sheep.  259 
 260 
 In people, the minimum effective concentrations reported for tramadol and M1 are 0.3 ± 0.2 261 
µg/mL (Lehmann et al., 1990) and 0.08 ± 0.03 µg/mL (Grond et al., 1999), respectively. In our 262 
study, tramadol in plasma was above the human therapeutic concentration up to 45 min after drug 263 
administration while the M1 plasma concentrations considered effective in people were maintained 264 
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in sheep plasma up to 2 h post treatment. Surprisingly, we found no mechanical antinociceptive 265 
effect of tramadol in the first hour after drug administration, when plasma levels of tramadol and 266 
M1 were similar to analgesic concentrations reported in humans.  267 
 268 
 Quantitative sensory testing methods have been used in conscious painful and non-269 
painful/healthy sheep in order to assess the efficacy of analgesic drugs, including opioids (Nolan et 270 
al., 1988; Waterman et al., 1991; Kyles et al., 1993; Musk et al., 2014), NSAIDs (Welsh and Nolan, 271 
1994,1995; Lizarraga and Chambers, 2006) and α2-agonists (Grant et al., 2001; Grant and Upton, 272 
2004; Musk et al., 2014). We found no statistically significant difference in MNT between groups 273 
which is consistent with other studies performed in conscious healthy sheep. Buprenorphine (6 274 
µg/kg IV) was found to exert antinociceptive activity in a thermal nociceptive threshold test but not 275 
in the mechanical one (Nolan et al., 1987b); butorphanol (0.1-0.4 mg/kg IV) did not cause any 276 
significant elevation in mechanical pressure threshold (Waterman et al., 1991); pethidine (5 mg/kg 277 
IV) increased thermal threshold for 30 min but pressure threshold only for a few minutes (Nolan et 278 
al., 1988) and pethidine plus fentanyl caused a brief increase in mechanical threshold values (Nolan 279 
et al., 1987a).  280 
 281 
 Clearly a more complete evaluation of analgesic effects of a drug should be performed using 282 
more than one type of stimulus (Tyers, 1980). Thermal nociceptive threshold testing was not 283 
performed in this study because of the unavailability of the equipment and for economic reasons, 284 
but also because it has been reported to cause skin damage in sheep (Musk et al., 2014), most likely 285 
because of the stoical attitude of this species. Moreover, when tramadol was tested in conscious 286 
horses at the dose of 2 mg/kg, no changes were detected with a thermal nociceptive threshold model 287 
(Dhanjal et al., 2009). 288 
 289 
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 The lack of efficacy of tramadol observed in the present study may be due to several reasons. 290 
It might be that the achieved plasma concentrations of tramadol were not sufficient to promote 291 
antinociception in sheep and that higher plasma concentrations would be required. Genetic 292 
variabilities were shown to affect tramadol metabolism in people (Pedersen et al., 2006) and this 293 
may also apply to sheep. A variation in the analgesic effect of xylazine in different breeds of sheep 294 
has been reported (Ley et al., 1990). Moreover, sheep tend to mask signs of nociception, although in 295 
the current study very clear behavioural end points to the MNT test were produced and the sheep 296 
did not reach the cut-out values. Xylazine, which has been shown to cause an increase in the 297 
mechanical nociceptive threshold in sheep (Nolan et al., 1987c), was not used as a positive control 298 
as it would have increased the mechanical nociceptive threshold but it would be difficult to 299 
differentiate between sedation and analgesia.  300 
 301 
 It should be noted that a major limitation of nociceptive threshold testing is that it does not 302 
provide the same stimulus as clinical pain (Love et al., 2011). It may be possible that the analgesic 303 
effects of tramadol would be detected in clinical pain states. 304 
 305 
 The MNT decreased with time in all groups, which might be explained by a sensitization to 306 
the MNT test. This finding is consistent with previous reports of MNT measurement in sheep 307 
(Stubsjoen et al., 2010) and could be another reason why no analgesic effect of tramadol was 308 
detected. On the other hand, in another report the mechanical nociceptive threshold did not vary 309 
over 14 days in conscious healthy sheep (Abu-Serriah et al., 2007). In our study, in order to prevent 310 
bias, the same observer performed the MNT test and animals were acclimatised to research 311 
personnel, equipment, procedures and stables.  312 
 313 
 After tramadol administration, adverse events, including muscle fasciculation, tremors, 314 
agitation and ataxia, were noticed in the majority of animals, but these were short lasting and self-315 
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limiting and not deemed to be clinically problematic. This is consistent with findings described in 316 
alpacas (Giorgi et al., 2010; Edmondson et al., 2012), llamas (Cox et al., 2011), and horses (Giorgi 317 
et al., 2007; Stewart et al, 2011). Although drugs were injected over 2 min, adverse events were still 318 
observed. In people, dose and speed of infusion of tramadol affect the incidence of adverse events 319 
(Grond and Sablotzki, 2004). In the clinical setting in sheep, a slow infusion rate, over 10 min, may 320 
produce less adverse effects.  321 
 322 
 Compared to saline, tramadol administration did not affect measured physiological parameters 323 
including heart rate, respiratory rate and rectal temperature. Other authors have also observed an 324 
absence of change in these parameters after epidural administration of tramadol in goats and cows 325 
(Bigham et al., 2010; Dehkordi et al., 2012). In contrast, a study conducted in lambs has shown 326 
changes in rectal temperature and heart and respiratory rate (Habibian et al., 2011). These 327 
incongruities might be the result of having adult versus juvenile subjects and differences in route of 328 
administration. In our work tramadol was shown not to affect gut motility; this might be due to the 329 
low affinity of tramadol for the µ-opioid receptor and thus tramadol may be advantageous in this 330 
species. Tramadol administered to horses at the dose of 2 mg/kg IV was shown not to alter the 331 
faecal output although a short lived (40 min) decrease in borborygmus score was reported (Dhanjal 332 
et al., 2009). Further studies could be performed to assess the effect of tramadol on gastrointestinal 333 
motility by quantification of faecal output (Love et al., 2012) or using radiopaque spheres (Sano et 334 
al., 2011). 335 
 336 
Conclusions 337 
 IV administration of tramadol at 4 and 6 mg/kg in sheep was associated with rapid 338 
metabolism and a transient presence of M1 in plasma; antinociceptive effects were not detected 339 
using an MNT model. This study provided pharmacokinetic data for tramadol in sheep but further 340 
studies are warranted to assess its clinical efficacy in animals experiencing pain. 341 
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Figure legends 521 
 522 
Fig. 1. Average tramadol (solid line, triangle) (--) and M1 (dotted line, square) (--) 523 
concentrations vs. time after IV administration of tramadol 4 mg/kg (a) and 6 mg/kg (b) (n = 6), 524 
respectively. Bars represent the standard deviation.  525 
 526 
Fig. 2. MNT values at the different time points in the three groups of sheep (n = 6). Saline = grey; 527 
T4 = light grey; T6= dark grey. Bars represent the standard deviation. 528 
Table 1 529 
Main average pharmacokinetic parameters of tramadol following tramadol IV administration at 4 530 
mg/kg and 6 mg/kg in sheep (n = 6) 531 
Dose 4 mg/kg 6 mg/kg 
Parameter Unit Mean SD Mean SD 
k10   1/h 6.895 7.350 2.210 0.381 
k12  1/h 7.652 10.137 1.658 1.188 
k21   1/h 3.102 1.243 3.062 1.269 
t 1/2 h 0.091 0.078 0.161 0.118 
t 1/2 h 0.671 0.419 0.573 0.116 
V1 L/kg 1.572 1.151 2.870 0.120 
CL1 L/kg/h 4.862 1.191 6.315 0.949 
V2  L/kg 1.694 0.890 1.415 0.796 
CL2  L/kg/h 4.466 1.473 4.732 3.509 
AUC 0-∞ μg/mL*h 0.870 0.236 0.968 0.145 
AUMC  μg/mL*h2 0.539 0.245 0.671 0.215 
MRT  h 0.651 0.337 0.686 0.137 
Vss L/kg 3.266 1.919 4.285 0.745 
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AUC 0-∞, area under serum concentration-time curve from time zero to infinity; 532 
AUMC, area under moment curve; CL1, clearance of central compartment; CL2, 533 
clearance of peripheral compartment; k10, the rate at which the drug leaves the 534 
system from the central compartment (the elimination rate); k12, the rate at which the 535 
drug passes from central to peripheral compartment; k21, the rate at which the drug 536 
passes from peripheral to central compartment; MRT, mean residence time; t½, 537 
distribution half-time; t½, elimination half-time; V1, volume of distribution in 538 
central compartment; V2, volume of distribution in peripheral compartment; Vss, 539 
volume of distribution at steady state. 540 
SD, standard deviation. 541 
Table 2 542 
Average pharmacokinetic parameters of M1 following tramadol IV administration at 4 mg/kg and 6 543 
mg/kg in sheep (n = 6) 544 
Dose 4 mg/kg 6 mg/kg 
Parameter Unit Mean SD Mean SD 
z  1/h 0.606 0.084 0.580 0.142 
t ½ z h 1.163 0.163 1.266 0.350 
Tmax obs h 0.373 0.334 0.402 0.267 
Cmax obs μg/mL 0.141 0.020 0.159 0.037 
AUC 0-∞ obs μg/mL*h 0.317 0.077 0.414 0.128 
MRT 0-∞ obs h 1.810 0.244 1.974 0.388 
AUC 0-∞ obs, area under serum concentration-time curve from 545 
time zero to infinity; Cmaxobs, Maximum concentration observed; 546 
MRT 0-∞ obs , mean residence time from time zero to infinity; 547 
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Tmaxobs, Time of maximum concentration observed; t½z, 548 
terminal half-time. 549 
SD, standard deviation. 550 
551 
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